Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29677296 | 1.00 | RET (0.66) | RETKDRROCK2EGFRMKNK1 | |
| SCHEMBL3580880 | 0.92 | RET (0.64) | RETKDRROCK2ABCG2ABCB1 | |
| SCHEMBL3588668 | 0.89 | RET (0.61) | RETKDRROCK2EGFRABCG2 | |
| SCHEMBL3593329 | 0.89 | RET (0.62) | RETKDRROCK2EGFRABCG2 | |
| SCHEMBL13154698 | 0.88 | RET (0.66) | RETKDRROCK2EGFRABCG2 | |
| SCHEMBL3583259 | 0.87 | ROCK2 (0.64) | RETKDRROCK2ABCG2ABCB1 | |
| SCHEMBL13154702 | 0.84 | RET (0.72) | RETKDRROCK2EGFRMKNK1 | |
| SCHEMBL3581389 | 0.84 | RET (0.61) | RETKDRROCK2EGFRABCG2 | |
| SCHEMBL3808492 | 0.83 | ROCK2 (0.59) | RETROCK2EGFRABCG2ABCB1 | |
| SCHEMBL3587684 | 0.83 | TGFBR1 (0.56) | KDRROCK2MKNK1ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | claimed |
| WO-2008022182-A1 | METHODS FOR PROMOTING COUPLING BETWEEN BONE FORMATION AND RESORPTION | THE UAB RESEARCH FOUNDATION (US) | 2008-02-21 | — | — | WO | claimed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | claimed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | claimed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | claimed |
| EP-4338751-B1 | COMBINATION OF SEPETAPROST AND NETARSUDIL FOR USE IN THE PROPHYLAXIS OR TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | SANTEN PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-12201602-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240293411-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION | 2024-09-05 | — | — | US | disclosed |
| US-20240245668-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-07-25 | — | — | US | disclosed |
| US-11974994-B2 | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-05-07 | — | — | US | disclosed |
| EP-4338751-A2 | MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND RHO-ASSOCIATED COILED-COIL CONTAINING PROTEIN KINASE INHIBITOR | Santen Pharmaceutical Co., Ltd. (JP) | 2024-03-20 | — | — | EP | disclosed |
| US-11918581-B2 | Combination therapy comprising JAK pathway inhibitor and rock inhibitor | INCYTE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2008022182-A1 | METHODS FOR PROMOTING COUPLING BETWEEN BONE FORMATION AND RESORPTION | THE UAB RESEARCH FOUNDATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | disclosed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060052367-A1 | Remedy for glaucoma comprising rho kinase inhibitor and beta-blocker | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20050245509-A1 | Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins | SANTEN PHARMACECUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1568382-A1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND &bgr;-BLOCKER | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1541151-A1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142313-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | RET 801/4885KDR 1115/4885ROCK2 3/4885 |
| US-11918581-B2 | Combination therapy comprising JAK pathway inhibitor and rock inhibitor | JAK1, ROCK1, JAK3 | RET 408/4885KDR 1777/4885ROCK2 4/4885 |
| US-12201602-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | CIT, ROCK1, ROCK2 | RET 2782/4885KDR 2844/4885ROCK2 3/4885 |
| US-11974994-B2 | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | PTGIS, PTGIR, PTGS1 | RET 4111/4885KDR 3135/4885ROCK2 539/4885 |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | CIT, PDE3A, PDE2A | RET 1575/4885KDR 605/4885ROCK2 8/4885 |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | RET 801/4885KDR 1115/4885ROCK2 3/4885 |
| US-20240245668-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | RET 4111/4885KDR 3135/4885ROCK2 539/4885 |
| US-20240293411-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | JAK1, ROCK1, JAK3 | RET 408/4885KDR 1777/4885ROCK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.